

## News Release

**Contacts:** Douglas Reynolds  
President  
Sunovion Pharmaceuticals Canada Inc.  
905-814-9145  
[douglas.reynolds@sunovion.com](mailto:douglas.reynolds@sunovion.com)

Susan Adler Alesina  
Vice President, Corporate Communications  
Sunovion Pharmaceuticals Inc.  
508-481-6700  
[susan.alesina@sunovion.com](mailto:susan.alesina@sunovion.com)

---

### **Sunovion Pharmaceuticals Canada Inc. Announces Company Name Change**

*Sepracor Pharmaceuticals, Inc. changes name, maintains commitment to developing scientifically-advanced central nervous system, cardiovascular disease and infectious disease therapies that improve patients' lives*

**Mississauga, Ontario, August 17, 2011** – Sunovion Pharmaceuticals Canada Inc. (Sunovion Pharmaceuticals Canada), formerly Sepracor Pharmaceuticals, Inc., announced today that it has formally changed its name. The change occurs as a result of the continued integration of Sunovion Pharmaceuticals Inc. (the U.S.-based parent company of Sunovion Pharmaceuticals Canada) and Dainippon Sumitomo Pharma Co., Ltd. (DSP), a multi-national pharmaceutical company located in Osaka, Japan. The majority of DSP's operations in North America and certain strategic international locations will now carry the Sunovion name.

"The name Sunovion represents two timeless forces: the strength of the sun and the power of human innovation. Together they represent the life affirming energy that drives our vision and inspires our people, who strive to realize that vision every day," said Douglas Reynolds, President, Sunovion Pharmaceuticals Canada. "As part of a growing global organization, this is an exciting time for Sunovion Pharmaceuticals Canada and, we look forward to expanding our product portfolio in the years ahead with potential launches in the areas of psychiatry and neurology."

More information about Sunovion Pharmaceuticals Canada Inc. is available at [www.sunovion.ca](http://www.sunovion.ca)

#### **About Sunovion Pharmaceuticals Canada Inc.**

Sunovion Pharmaceuticals Canada Inc. is focused on the development and commercialization of prescription products in Canada. In addition to commercializing Sunovion Pharmaceuticals Inc.'s products, our strategy is to license pharmaceutical products that meet the needs of patients and the Canadian health care system, currently focusing on cardiovascular disease, infectious disease and central nervous system (CNS) disorders. More information about Sunovion Pharmaceuticals Canada inc. is available at [www.sunovion.ca](http://www.sunovion.ca)

Sunovion Pharmaceuticals Canada Inc., a subsidiary of the U.S. based Sunovion Pharmaceuticals Inc. is headquartered in Mississauga, Ontario. Sunovion Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at [www.sunovion.com](http://www.sunovion.com).

**About Sunovion Pharmaceuticals Inc. (Sunovion)**

Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the central nervous system (CNS) and respiratory disease areas and improve the lives of patients and their families. Sunovion's drug development program, together with its corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products including LATUDA<sup>®</sup> brand lurasidone HCl, LUNESTA<sup>®</sup> brand eszopiclone, XOPENEX<sup>®</sup> brand levalbuterol HCl Inhalation Solution, XOPENEX HFA<sup>®</sup> brand levalbuterol tartrate inhalation aerosol, BROVANA<sup>®</sup> brand aformoterol tartrate inhalation solution, OMNARIS<sup>®</sup> brand ciclesonide nasal spray and ALVESCO<sup>®</sup> brand ciclesonide HFA inhalation aerosol.

Sunovion, an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at [www.sunovion.com](http://www.sunovion.com).

**About Dainippon Sumitomo Pharma Co., Ltd. (DSP)**

DSP is a multi-billion dollar, top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. DSP aims to produce innovative pharmaceutical products in the CNS field, which has been designated as the key therapeutic area and will also focus in on other specialty disease categories with significant unmet medical needs, which are designated as frontier therapeutic areas. DSP is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at [www.ds-pharma.com](http://www.ds-pharma.com).

LATUDA<sup>®</sup> is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd. LUNESTA, XOPENEX, XOPENEX HFA and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc. OMNARIS and ALVESCO are registered trademarks of Nycomed GmbH.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. © 2011 Sunovion Pharmaceuticals Inc.

For a copy of this release or any recent release,  
visit Sunovion Pharmaceutical Canada's web site at [www.sunovion.ca](http://www.sunovion.ca)

###